Johnson & Johnson announced on Friday that its coronavirus vaccine was 66 percent effective against the pathogen, and the company will ask U.S. regulators for approval in February.
Unlike the Pfizer-BioNTech and Moderna candidates, Johnson & Johnson’s vaccine is administered in one shot. The vaccine uses a relatively new technology to deliver a coronavirus gene into the body by using a modified form of the common cold. The gene instructs bodily cells to make a protein similar to coronavirus, which wards off infection.
While the vaccine is not as effective as those of Pfizer and Moderna, Johnson & Johnson’s vaccine is still strong enough to give widespread protection from coronavirus. The company has the ability to ship millions of doses, and a February approval would add the vaccine to the tools currently being used to fight the pandemic.
Comments
Post a Comment